Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II With safety-run-in Multicenter Study of Momelotinib in Patients With VEXAS Syndrome With or Without Associated Myelodysplastic Syndrome

NCT07098936 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT07098936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07098936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II With safety-run-in Multicenter Study of Momelotinib in Patients With VEXAS Syndrome With or Without Associated Myelodysplastic Syndrome
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2025
Completion date
November 30, 2028
Enrollment
57 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myelo dysplastic syndrome, vexas syndome